Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients

Table 5

HOMA-IR-based subgroup analysis of sociodemographic and clinical characteristics in the olanzapine-treated group ().

	IR ()	Non-IR ()
Age (years)			0.291
Gender (F/M)	31/27	24/19	0.813
Body weight (kg)			0.018
BMI			0.001
Physical activity index^a			0.936
Smoking (Y/N)	17/41	10/33	0.497
Drinking (Y/N)	10/48	7/36	0.559
Dosage (mg/d)^b			0.009
Duration of olanzapine use (year)			0.068
Duration of illness (year)			0.002
PANSS			0.468

^aPhysical activity . ^bOlanzapine medication dosages were transformed to chlorpromazine equivalent dosages.